Literature DB >> 23494107

Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?

Julien Edeline1, Laurence Lenoir, Karim Boudjema, Yan Rolland, Anne Boulic, Fanny Le Du, Marc Pracht, Jean-Luc Raoul, Bruno Clément, Etienne Garin, Eveline Boucher.   

Abstract

BACKGROUND: Contralateral hypertrophy after (90)Y radioembolization has been described in case reports, but the incidence and quantitative extent of liver volume modifications after this therapy are unknown.
METHODS: This retrospective study examined patients with hepatocellular carcinoma and underlying cirrhosis treated by (90)Y radioembolization. The main inclusion criteria were unilateral treatment, no prior liver surgery, and computed tomographic scans allowing for volumetric assessments. Treated, tumor, and contralateral liver volumes were measured. Whole liver volume and the ratio of contralateral to total functional liver volume after a virtual hepatectomy were calculated.
RESULTS: Data of 34 patients were analyzed. Response rates were 26 % according to Response Evaluation Criteria in Solid Tumors (RECIST) and 63 % according to modified RECIST. Median overall survival was 13.5 months. Median treated volume decreased from 938 mL (interquartile range [IQR] = 719) to 702 mL (IQR = 656) (p < 0.001), while median contralateral volume increased from 724 mL (IQR = 541) to 920 mL (IQR = 530) (p < 0.001). The whole liver volume remained stable, with a median volume of 1,702 mL (IQR = 568) versus 1,577 mL (IQR 670), respectively (p = 0.55). The mean maximal increase in contralateral volume was 42 % (95 % confidence interval 16-67). Overall, 13 patients (38.2 %) exhibited increases greater than 30 %, while 13 patients (38.2 %) showed no increase or showed increases less than 10 %. The median ratio of contralateral to total functional liver volume increased from 48.5 to 64.9 % (p < 0.001), with the proportion of patients with a ratio of ≥50 % increasing from 47.1 to 67.6 % (p = 0.013).
CONCLUSIONS: (90)Y radioembolization induced frequent and similar increases in functional liver remnant volume compared with portal vein embolization. This technique should be tested in a prospective study phase 2 study before liver resection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494107     DOI: 10.1245/s10434-013-2906-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  31 in total

Review 1.  Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.

Authors:  Samdeep K Mouli; Laura W Goff
Journal:  Curr Treat Options Oncol       Date:  2017-10-27

Review 2.  Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.

Authors:  Julien Edeline; Marine Gilabert; Etienne Garin; Eveline Boucher; Jean-Luc Raoul
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

3.  Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Jon Bell; Carlo Chiesa; Kirk Fowers; Bonnie Hamilton; Joseph Herman; S Cheenu Kappadath; Thomas Leung; Lorraine Portelance; Daniel Sze; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-16       Impact factor: 9.236

Review 4.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

5.  Radioembolization as an adjunct therapy to the resection of liver tumors.

Authors:  Mercedes Iñarrairaegui; Bruno Sangro
Journal:  Hepat Oncol       Date:  2015-11-06

Review 6.  Radioembolization with yttrium-90 glass microspheres for patients with hepatocellular carcinoma: a review.

Authors:  Jöerg Friedrich Schlaak
Journal:  Hepat Oncol       Date:  2014-12-11

Review 7.  Radioembolization for hepatocellular carcinoma: current role and future directions - the medical oncologist's perspective.

Authors:  Peter Gibbs; Jeanne Tie; Lourens Bester
Journal:  Hepat Oncol       Date:  2015-04-20

8.  Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.

Authors:  Robert J Lewandowski; Jeet Minocha; Khairuddin Memon; Ahsun Riaz; Vanessa L Gates; Robert K Ryu; Kent T Sato; Reed Omary; Riad Salem
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-10       Impact factor: 9.236

9.  One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization.

Authors:  Cecilia Servajean; Marine Gilabert; Gilles Piana; Geneviève Monges; Jean-Robert Delpero; Isabelle Brenot; Jean-Luc Raoul
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 10.  A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.

Authors:  Jin-Yao Teo; John C Allen; David C Ng; Su-Pin Choo; David W M Tai; Jason P E Chang; Foong-Khoon Cheah; Pierce K H Chow; Brian K P Goh
Journal:  HPB (Oxford)       Date:  2015-12-11       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.